Radiation Therapy for Patients With Autoimmune Disease — What Lupus and Scleroderma Actually Change

For most autoimmune conditions, yes — radiation is still given, with closer monitoring. The exception is active connective tissue disease, above all scleroderma and to a lesser degree lupus, where published series report more severe skin and late tissue reactions. Your radiation oncologist and rheumatologist decide together, case by case.

This is a real clinical issue that is almost invisible in public information. Search for radiation therapy and you will find pages about side effects, machines and schedules. You will rarely find the sentence that matters to you: an autoimmune condition changes the risk profile of radiation, and it changes it by different amounts depending on which condition you have.

The concern has a simple biological logic. Radiation works partly by damaging cells and letting normal tissue repair itself afterwards. Connective tissue diseases already involve inflammation and scarring in exactly that tissue. When repair is already impaired, the same dose can leave more fibrosis, more skin breakdown and slower healing than it would in someone without the condition.

Two things follow from that. First, your diagnosis is a flag, not a verdict — it triggers a closer look at technique, dose and field size, and a documented risk conversation. Second, that conversation has to happen before planning starts, not after a reaction appears. Tell the radiation oncologist about your autoimmune condition at the very first appointment, even if it has been quiet for years.

Your radiotherapy is delivered at an NABH-accredited partner centre; CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout — including the joint review with your rheumatologist and the monitoring that follows.

Indicative guidance only, as of August 2026, drawn from NCCN and ASTRO commentary on treating patients with connective tissue disease. This table describes what your team assesses. It does not decide whether radiation is suitable for you, and no eligibility can be assumed from it.

In published series, yes — more severe acute skin reactions and more late fibrosis than expected. The signal is strongest in systemic sclerosis. It is weaker and less consistent in lupus. The studies are small and retrospective, so the numbers are not firm, and NCCN and ASTRO guidance treats this as an individual risk discussion.

It helps to separate two kinds of reaction. Acute effects appear during treatment and in the weeks after it — redness, soreness, peeling, tiredness. These settle in most patients, and in autoimmune disease they may be more intense and take longer to settle. Late effects appear months to years later — hardening and tightening of the treated area, shrinkage, colour change, and in a small number of patients skin that breaks down and heals poorly. It is the late effects that drive the caution in scleroderma.

The risk is also not spread evenly. It rises when a large volume of skin sits in the high-dose region, when the field is wide, and when the disease is active at the time of treatment. It is lower when only a small, deep target is being treated and skin can largely be spared. This is why a patient with lupus having a small, deep-seated target may be advised very differently from a patient with scleroderma needing a broad surface field.

One clarification patients often ask about. Skin sensitivity to sunlight in lupus is not the same biological process as a reaction to radiotherapy, and being photosensitive does not by itself predict how your skin will handle radiation. It does mean skin in the treated area is reviewed more closely, and that any new rash during treatment is reported rather than waited out.

In many patients, yes. Very few autoimmune conditions are treated as an absolute barrier. What changes is the depth of the assessment beforehand and the care taken with technique. Scleroderma is the most common relative contraindication, meaning the benefit has to clearly outweigh a higher risk. No page can tell you your own answer.

What follows is the framework your team works through, not a recommendation. It is worth reading before your appointment so you know what you will be asked and what to bring.

• 1. The exact diagnosis is confirmed — an overlap syndrome, an undifferentiated connective tissue disease and a firm diagnosis of systemic sclerosis are not weighed the same way, so your rheumatology records matter more than a label.
• 2. Disease activity now is assessed — quiet, stable disease is a very different starting point from an active flare, and activity is judged from your current examination and blood tests, not from your history.
• 3. Organ involvement is mapped against the field — lung, kidney, heart, bowel and skin involvement matter most when those organs sit near the target, and much less when they do not.
• 4. Your medicine list is reviewed with your rheumatologist — timing, pausing or continuing an immune-related treatment is their call, made together with the radiation oncologist and never by you alone.
• 5. The plan is redesigned to lower risk where it can be — smaller fields, tighter conformality, sparing skin where the target allows, and a fractionation choice suited to a higher-risk profile.
• 6. The alternatives are compared honestly — the real question is not whether radiation carries extra risk for you, but how that risk compares with the other options open to you for this cancer.

Consent conversations on this cluster are longer than usual, and that is deliberate. You should leave the appointment able to say what the extra risk is in your case, what has been changed to reduce it, and what would be done if a severe reaction appeared.

Skin care during treatment is agreed with your team rather than improvised. Use only a rinse, wash or moisturiser your radiation team has approved for the treated area, and tell them before you start anything new — including anything your rheumatologist or dermatologist prescribes for your skin. Report a new rash, a raw patch or unexpected pain the same day it appears.

• How much extra risk does my condition add in my case? Ask for it in plain terms — which tissue, which kind of reaction, and roughly when it would show up.
• Has my rheumatologist been consulted? Ask when that conversation happened and what was agreed about disease control and medicine timing.
• What has been changed in my plan to lower the risk? Field size, dose, schedule and skin sparing are the usual answers.
• How often will I be reviewed, and by whom? Ask specifically who checks the skin and the treated area, and how to reach them between visits.
• What would make you stop or change the treatment? Knowing the threshold in advance makes it easier to report a reaction early.
• What are my alternatives, and what do they cost me? Not in money — in risk, time and effect on the cancer being treated.

Autoimmune disease is one of several situations where patients quietly rule themselves out of radiation before anyone has assessed them. The pattern is the same each time — a real clinical consideration gets mistaken for a closed door. If a second condition is part of your situation, these pages cover the same ground for it.

Where the immune system is suppressed for a different reason, radiation therapy in HIV-positive patients covers what changes and what does not. Where following instructions on the couch is the difficulty rather than tissue tolerance, see radiation therapy for patients with dementia or cognitive impairment. Where body size affects positioning accuracy and machine limits, see radiation therapy for patients with severe obesity. And where joint stiffness or pain from your condition makes the daily position hard to hold, radiation for patients who cannot lie flat or still sets out the positioning workarounds. For planning, safety and what to expect across the whole treatment, start at the Radiation Therapy hub at CION Cancer Clinics.

Treated With Another Condition in the Picture

Every autoimmune history is different — talk to our team about yours before ruling treatment in or out.